Melinta Therapeutics
Melinta Therapeutics
300 George Street, Suite 301
New Haven, CT 06511
Phone: (203) 624-5606Website: https://melinta.com/Careers: melinta.com/join-our-team
Latest news
- FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
15 March 2021 - FDA Approves Baxdela (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
24 October 2019 - Melinta Therapeutics Announces FDA Approval of Baxdela (delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
19 June 2017 - Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
24 October 2016 - Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
11 February 2014
Drugs Associated with Melinta Therapeutics
Melinta Therapeutics manufactures, markets and/or distributes more than 5 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Baxdela
Generic name: delafloxacin Drug class: quinolones and fluoroquinolones |
1 review | 10 / 10 |
|
Kimyrsa
Generic name: oritavancin Drug class: glycopeptide antibiotics |
||
|
Minocin for Injection
Generic name: minocycline Drug class: tetracyclines |
||
|
Orbactiv
Generic name: oritavancin Drug class: glycopeptide antibiotics |
2 reviews | 1.0 / 10 |
|
Vabomere
Generic name: meropenem/vaborbactam Drug class: carbapenems/beta-lactamase inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||